Phase I Study of U3P1287/01, Including Patients With Advanced Solid Tumors

Overview

This is a Phase 1 clinical study to investigate the safety, pharmacokinetics, and pharmacodynamics of U3-1287 (AMG 888), a fully human monoclonal antibody targeting the HER3 receptor, in patients with advanced solid tumors. Eligible patients will have disease that is refractory or resistant to standard treatments or for which no standard therapy exists. The study will be conducted in two parts; a dose escalation (Part 1) and a dose expansion (Part 2). The hypothesis for this study is that U3-1287 (AMG888) will be safe and well tolerated in patients with advanced solid tumors and will show initial evidence of anti-tumor activity.

Full Title of Study: “A Phase I, Open-label, Dose-Finding Study to Assess the Safety and Tolerability of U3-1287 (AMG 888), a Human Monoclonal Antibody Targeting HER3 in Patients With Advanced Solid Tumors.”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Non-Randomized
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: July 2010

Interventions

  • Drug: U3-1287 (AMG888)
    • IV Infusion Dose Escalation (Part 1) – 5 Dose Cohorts Dose Expansion (Part 2) – 30 patients

Arms, Groups and Cohorts

  • Experimental: 1

Clinical Trial Outcome Measures

Primary Measures

  • To evaluate the safety and tolerability of U3-1287 (AMG888) in patients with advanced solid tumors
    • Time Frame: Lenth of study
  • To evaluate maximum tolerated dose (MTD) of U3-1287(AMG888) when administered intravenously to patients with advanced solid tumors
    • Time Frame: Lenth of study

Secondary Measures

  • Pharmacokinetic Parameters
    • Time Frame: Length of study
  • Pharmacodynamic Parameters
    • Time Frame: Length of study
  • Human anti-human antibody profile for U3-1287(AMG888)
    • Time Frame: Length of study

Participating in This Clinical Trial

Key Inclusion Criteria:

  • Pathologically or cytologically documented advanced solid tumor that is refractory to standard treatment, for which no standard therapy is available, or the patient refuses standard therapy. – Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2. – Men or women at least 18 years of age – Adequate hematologic, cardiac, renal, hepatic, metabolic, and coagulation function Key Exclusion Criteria:

  • Presence of untreated or symptomatic brain metastasis. – Presence of ascites or pleural effusion requiring chronic medical intervention. – Uncontrolled hypertension – Concurrent or previous (within 1 week of study day 1) anticoagulation therapy, except low-dose warfarin (≤ 2 mg/day) or low dose,low molecular weight heparin for prophylaxis against central venous catheter thrombosis. – Recent major surgical procedure or not yet recovered from major surgery – Recent participation in clinical drug trials. – Participation in other investigational procedures. – Unresolved toxicities from prior anti-cancer therapy – Patient who is pregnant (e.g. positive human choriogonadotropin [HCG] test) or nursing.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • U3 Pharma GmbH
  • Provider of Information About this Clinical Study
    • Dr Alan Boyd MD, U3 Pharma GmbH

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.